COVID-19 VI Providence
$6,400,000.00
Grant Value
2021-22
Fiscal Year
Description
Providence Therapeutics, Canadas leading mRNA vaccine manufacture, is manufacturing an mRNA vaccine against COVID-19. The company is in the R&D phases to demonstrate the preclinical and clinical efficacy of PTX-COVID19-B.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Grant Details
Recipient
Providence Therapeutics Holdings Inc.
Location
Calgary, AB T2Z 3P4
Agreement Details
Number: 957288
Reference: 172-2021-2022-Q2-957288
Timeline
Start: Sept. 1, 2020
End: July 30, 2021
Program
Industrial Research Assistance Program Contributions to Firms
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or …
Sector
Manufacturing (3254)
Your Contribution
Calculate how much you personally contributed to this grant through your taxes.
Calculate My Share